Abstract |
Diffuse cutaneous mastocytosis is a less common but potentially life-threatening variant of childhood mastocytosis. Here we report 2 children with diffuse cutaneous mastocytosis in whom an activating somatic KIT mutation was detected. Treatment with imatinib, a KIT inhibitor, resulted in resolution of the lesions and were well tolerated by the patients.
|
Authors | Marie-Anne Morren, Anne Hoppé, Marleen Renard, Maria Debiec Rychter, Anne Uyttebroeck, Patrice Dubreuil, Ludovic Martin |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 162
Issue 1
Pg. 205-7
(Jan 2013)
ISSN: 1097-6833 [Electronic] United States |
PMID | 23069194
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2013 Mosby, Inc. All rights reserved. |
Chemical References |
- Benzamides
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Imatinib Mesylate
|
Topics |
- Benzamides
- Female
- Humans
- Imatinib Mesylate
- Infant
- Mastocytosis, Cutaneous
(drug therapy)
- Piperazines
(therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Pyrimidines
(therapeutic use)
|